Doheny Asset Management /Ca Uni Qure N.V. Transaction History

Doheny Asset Management /Ca

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$4.39 - $5.43 $118,881 - $147,044	27,080 New	27,080 $121,000
Q4 2020 Feb 26, 2021	SELL	$35.35 - $50.67 $855,081 - $1.23 Million	-24,189 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$35.98 - $47.66 $644,905 - $854,257	17,924 Added 286.1%	24,189 $1.73 Million
Q3 2020 Nov 12, 2020	SELL	$35.98 - $47.66 $748,923 - $992,042	-20,815 Reduced 76.86%	6,265 $231,000
Q2 2020 Aug 18, 2020	BUY	$45.06 - $67.74 $130,268 - $195,836	2,891 Added 11.95%	27,080 $1.22 Million
Q4 2019 Feb 11, 2020	BUY	$37.13 - $74.62 $117,145 - $235,426	3,155 Added 15.0%	24,189 $1.73 Million
Q3 2019 Nov 15, 2019	SELL	$39.36 - $76.8 $79,546 - $155,212	-2,021 Reduced 8.77%	21,034 $828,000
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $417,331 - $650,122	7,910 Added 52.23%	23,055 $1.8 Million
Q1 2019 May 14, 2019	BUY	$27.39 - $68.41 $148,590 - $371,124	5,425 Added 55.81%	15,145 $903,000
Q4 2018 Feb 13, 2019	BUY	$22.8 - $33.93 $221,616 - $329,799	9,720 New	9,720 $280,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Doheny Asset Management /Ca, based on Form 13F filings with the SEC.

Stay updated on Doheny Asset Management /Ca with notifications on news.